Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles.

Journal Article (Journal Article)

Measles remains a principal cause of worldwide mortality, in part because young infants cannot be immunized effectively. Development of new vaccines has been hindered by previous experience with a formalin-inactivated vaccine that predisposed to a severe form of disease (atypical measles). Here we have developed and tested potential DNA vaccines for immunogenicity, efficacy and safety in a rhesus macaque model of measles. DNA protected from challenge with wild-type measles virus. Protection correlated with levels of neutralizing antibody and not with cytotoxic T lymphocyte activity. There was no evidence in any group, including those receiving hemagglutinin-encoding DNA alone, of 'priming' for atypical measles.

Full Text

Duke Authors

Cited Authors

  • Polack, FP; Lee, SH; Permar, S; Manyara, E; Nousari, HG; Jeng, Y; Mustafa, F; Valsamakis, A; Adams, RJ; Robinson, HL; Griffin, DE

Published Date

  • July 2000

Published In

Volume / Issue

  • 6 / 7

Start / End Page

  • 776 - 781

PubMed ID

  • 10888926

International Standard Serial Number (ISSN)

  • 1078-8956

Digital Object Identifier (DOI)

  • 10.1038/77506


  • eng

Conference Location

  • United States